Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1200820100100040239
Oriental Pharmacy and Experimental Medicine
2010 Volume.10 No. 4 p.239 ~ p.253
Coenzyme Q10: a progress towards the treatment of neurodegenerative disease
Kumar Peeyush

Kumar Pramod
Ram Alpana
Kumar Mithilesh
Kumar Rajeev
Abstract
Coenzyme (, or ubiquinone) is an electron carrier of the mitochondrial respiratory chain (electron transport chain) with antioxidant properties. In view of the involvement of in oxidative phosphorylation and cellular antioxidant protection a deficiency in this quinone would be expected to contribute to disease pathophysiology by causing a failure in energy metabolism and antioxidant status. Indeed, a deficit in status has been determined in a number of neuromuscular and neurodegenerative disorders. Primary disorders of biosynthesis are potentially treatable conditions and therefore a high degree of clinical awareness about this condition is essential. A secondary loss of status following HMG-CoA reductase inhibitor (statins) treatment has been implicated in the pathophysiology of the myotoxicity associated with this pharmacotherapy. and its analogue, idebenone, have been widely used in the treatment of neurodegenerative and neuromuscular disorders. These compounds could potentially play a role in the treatment of mitochondrial disorders, Parkinson¡¯s disease, Huntington¡¯s disease, amyotrophic lateral sclerosis, Friedreich¡¯s ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of , as well as the rationale and the role in clinical practice of supplementation in different neurological diseases, from primary deficiency to neurodegenerative disorders. These will help in future for treatment of patients suffering from neurodegenerative disease.
KEYWORD
Coenzyme Q10, Antioxidant, Ageing, Oxidative stress, Neurodegenerative diseases
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)